Clinical Takeaway
In this phase 3 randomized controlled trial, a full-spectrum cannabis extract (VER-01) was evaluated in 820 adults with chronic low back pain over a 12-week double-blind period followed by longer-term open-label phases. The trial was designed to assess both efficacy and safety against placebo in a condition where current treatments remain inadequate. Results from this study provide clinical-grade evidence regarding whether full-spectrum cannabis extract offers a meaningful, measurable benefit for one of the most prevalent pain conditions globally.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by providing rigorous evidence for cannabis-derived therapy in chronic low back pain, a condition affecting over 500 million people globally where current pharmacologic options demonstrate limited efficacy and significant adverse effect profiles. The multicenter randomized placebo-controlled design with 820 participants establishes the efficacy and safety profile necessary for clinical decision-making and potential regulatory approval of VER-01 as an alternative to opioids and other conventional analgesics. These findings could meaningfully expand the therapeutic armamentarium for CLBP management, particularly for patients who are opioid-intolerant or require alternatives due to abuse potential.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial of a full-spectrum cannabis extract for chronic low back pain offers meaningful data in a therapeutic area where conventional options remain suboptimal, though several practical considerations warrant careful interpretation by clinicians. The relatively large sample size and double-blind design strengthen confidence in efficacy signals, but we should note that full-spectrum extracts contain variable cannabinoid and terpene profiles that may differ between batches, complicate mechanistic understanding, and create reproducibility challenges across real-world settings. The 12-week primary phase is reasonably adequate for assessing pain outcomes, though longer-term safety and efficacy data remain particularly important given cannabis’s neuropsychiatric potential and drug interaction liability with common pain medications. Individual patient factors including age, comorbidities, concomitant medications, driving status, and personal or family history of cannabis use disorder or psychosis should inform shared decision-making, as trial populations often exclude or underrepresent such higher-risk groups. For eligible patients with documented CLBP
| |